Biologics, Module 4
TV time
IL-17 drives inflammation in the skin and spine. Think of it as an R-rated channel — you must be SEVENTEEN to watch.
“SECU-rity checks IDs at SEVENTEEN — but Crohn’s gets cancelled from the screen.”
Secukinumab and ixekizumab target IL-17A only. Bimekizumab targets both IL-17A and IL-17F.
“The BI in BImekizumab = two targets. IL-17A and IL-17F. Every other…
